Abstract
There is growing evidence that Rho-kinase contributes to cardiovascular disease, which has made Rho-kinase a target for the treatment of human diseases. To date, the only Rho-kinase inhibitor employed clinically in humans is fasudil, which has been used for the prevention of cerebral vasospasm and subsequent ischemic injury after surgery for subarachnoid hemorrhage (SAH). A number of pathological processes, in particular hemodynamic dysfunctions and inflammatory reactions, are thought to be related in the pathogenesis of delayed cerebral vasospasm and subsequent ischemic injury after SAH. This review focuses on fasudil’s pleiotropic therapeutic effects: amelioration of hemodynamic dysfunction and inflammation, and discusses in detail the clinical studies on fasudil administered after the occurrence of SAH.
Keywords: Cerebral vasospasm, fasudil, hydroxyfasudil, pleiotropic therapeutic effects, Rho-kinase, subarachnoid hemorrhage.
Current Vascular Pharmacology
Title:Pleiotropic Effects of the Rho-kinase Inhibitor Fasudil After Subarachnoid Hemorrhage: A Review of Preclinical and Clinical Studies
Volume: 12 Issue: 5
Author(s): Shin-ichi Satoh, Ichiro Ikegaki, Koh Kawasaki, Toshio Asano and Masato Shibuya
Affiliation:
Keywords: Cerebral vasospasm, fasudil, hydroxyfasudil, pleiotropic therapeutic effects, Rho-kinase, subarachnoid hemorrhage.
Abstract: There is growing evidence that Rho-kinase contributes to cardiovascular disease, which has made Rho-kinase a target for the treatment of human diseases. To date, the only Rho-kinase inhibitor employed clinically in humans is fasudil, which has been used for the prevention of cerebral vasospasm and subsequent ischemic injury after surgery for subarachnoid hemorrhage (SAH). A number of pathological processes, in particular hemodynamic dysfunctions and inflammatory reactions, are thought to be related in the pathogenesis of delayed cerebral vasospasm and subsequent ischemic injury after SAH. This review focuses on fasudil’s pleiotropic therapeutic effects: amelioration of hemodynamic dysfunction and inflammation, and discusses in detail the clinical studies on fasudil administered after the occurrence of SAH.
Export Options
About this article
Cite this article as:
Satoh Shin-ichi, Ikegaki Ichiro, Kawasaki Koh, Asano Toshio and Shibuya Masato, Pleiotropic Effects of the Rho-kinase Inhibitor Fasudil After Subarachnoid Hemorrhage: A Review of Preclinical and Clinical Studies, Current Vascular Pharmacology 2014; 12 (5) . https://dx.doi.org/10.2174/1570161112666140613115813
DOI https://dx.doi.org/10.2174/1570161112666140613115813 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Therapeutic Target of Cerebral Hemorrhagic Stroke: Matrix Metalloproteinase- 9
Current Drug Targets Hypoxia-Inducible Factor-1 in Arterial Disease: A Putative Therapeutic Target
Current Vascular Pharmacology Assessment of Vascular Geometry for Bilateral Carotid Artery Ligation to Induce Early Basilar Terminus Aneurysmal Remodeling in Rats
Current Neurovascular Research Infection, Infectious Agents and Vascular Disease
Reviews on Recent Clinical Trials Anesthetic and Adjunctive Drugs for Fast-Track Surgery
Current Drug Targets Use of Human Umbilical Cord Blood (HUCB) Cells to Repair the Damaged Brain
Current Neurovascular Research Cardiovascular Imaging in Thromboembolic Risk Stratification for Atrial Fibrillation: Recent Patents and Current Practice
Recent Patents on Medical Imaging Crosstalk Between the Angiotensin and Endothelin-System in the Cerebrovasculature
Current Neurovascular Research Vitamin D Metabolites and/or Analogs: Which D for Which Patient?
Current Vascular Pharmacology Modification of Decoy Oligodeoxynucleotides to Achieve the Stability and Therapeutic Efficacy
Current Topics in Medicinal Chemistry Cellular Mechanisms of Bypass Vein Graft Arterialization and Approaches to Attenuate Graft Remodeling
Vascular Disease Prevention (Discontinued) The Urokinase Plasminogen Activator System: Role in Malignancy
Current Pharmaceutical Design Multi-scale LBP and SVM Classification to Identify Diabetic Retinopathy in Lesions
Current Medical Imaging Contextualizing the Genes Altered in Bladder Neoplasms in Pediatric and Teen Patients Allows Identifying Two Main Classes of Biological Processes Involved and New Potential Therapeutic Targets
Current Genomics Meet Our Section Editor
Central Nervous System Agents in Medicinal Chemistry Genetic Polymorphisms of Type-1 and Type-2 Inflammatory Cytokines in Ischaemic Stroke
Vascular Disease Prevention (Discontinued) The Brain, the Penis and Steroid Hormones: Clinical Correlates with Endothelial Dysfunction
Current Pharmaceutical Design The Possibility of Novel Antiplatelet Peptides: The Physiological Effects of Low Molecular Weight HSPs on Platelets
Current Pharmaceutical Design Extraction of Quantitative Anatomical Information from Coronary Angiographies
Current Bioinformatics Leukotrienes and Atherosclerosis
Current Drug Targets